HBPCF (Helix BioPharma) Debt-to-Asset : 0.02 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBPCF Helix BioPharma Corp HBPCF
32 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Debt-to-Asset?

Helix BioPharma HBPCF 32 Debt-to-Asset is 0.02 as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 32/100.

Helix BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.26 Mil. Helix BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.00 Mil. Helix BioPharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Apr. 2026 was $15.55 Mil. Helix BioPharma's debt to asset for the quarter that ended in Apr. 2026 was 0.02.

Helix BioPharma  (OTCPK:HBPCF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Helix BioPharma Debt-to-Asset Related Terms

Helix BioPharma Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Debt-to-Asset Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.66 0.00 0.00 0.02

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.02 0.02 0.02 0.02

HBPCF vs VRTX, REGN, RVMD: Debt-to-Asset Comparison

For the Biotechnology subindustry, Helix BioPharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Debt-to-Asset falls into.


HBPCF
32GF Score
Helix BioPharma Corp HBPCF
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Helix BioPharma's Debt-to-Asset for the fiscal year that ended in Jul. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.245 + 0) / 13.733
=0.02

Helix BioPharma's Debt-to-Asset for the quarter that ended in Apr. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.261 + 0) / 15.546
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.02 mean?
Helix BioPharma (HBPCF) has a Debt-to-Asset of 0.02 as of Apr. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's Debt-to-Asset too high?
Helix BioPharma's current Debt-to-Asset is 0.02. Overall, Helix BioPharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Debt-to-Asset compare to VRTX and REGN?
Helix BioPharma's Debt-to-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current Debt-to-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Debt-to-Asset of 0.02. The current Debt-to-Asset is 0.02. Helix BioPharma's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Debt-to-Asset is 0.02 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
32GF Score

Get the complete analysis for HBPCF

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price